智通财经APP获悉，诺诚健华(09969)涨超3%，截至发稿，涨3.5%，报18.63港元，成交额1.33亿港元。
消息面上，诺诚健华拟于8月19日(下周二)举行董事会会议以审批中期业绩。中金此前指出，诺诚健华首季收入按年升1.3倍，净利润按年扭亏为盈至1800亿元，业绩超过该行预期，主因公司核心产品奥布替尼高增长以及公司与Prolium达成授权许可的首付款确认。该行考虑到诺诚健华的奥布替尼销售超预期，上调公司今明两年盈利预测，分别由原预期的亏损4.36亿元和2.56亿元收窄至亏损4.15亿元和2.25亿元。
据了解，奥布替尼是诺诚健华研发的BTK抑制剂，主要用于治疗慢性淋巴瘤，其市场销售份额呈逐步上升趋势，在国内BTK抑制剂市场中占据重要地位。2024年，奥布替尼销售收入超10亿元，同比增长49.14%，在国内BTK抑制剂市场份额达30%。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.